Yet they are still in contract. From the FGEN side there was some language on their call that indicated discussions were still ongoing and that AZN had certain contractual obligations.
So it remains to be seen. It would not be surprising for them to exit the US market, however there is still application in myelodysplastic syndromes (MDS) and other non CKD anemia. I don't see them having an immediate and costless exit.
News 
Market Data 
Discover 
AI
